Fresh analysis suggests that patients who discontinue new weight-loss injections like Wegovy and Mounjaro may regain shed pounds far faster than those who end traditional diet and exercise plans.
Findings released in a major medical journal shows that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing such drugs should be informed of the risk of fast weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight within about one and a half years.
Weighing Treatments
The study, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with conventional dieting.
The team emphasize that people who shed pounds through diet and exercise usually see a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Nutrition scientists suggest the mechanism of the jabs explains the amplified regain.
These medications imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians say that, given the high risk of relapse, the therapy is often long-term.
This perspective is echoed by drug manufacturers, who say that the findings "emphasize the persistent nature of obesity," similar to managing conditions like hypertension.
Patient Accounts
People who have come off the jabs report a intense return of cravings.
"I experienced a trigger flipping and you become starving," said a patient.
The struggle is worsened if users have not adopted lasting lifestyle or habit modifications during treatment.
Growing Adoption
Survey data show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among women than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent fix and lasting health benefits hinges on integrated lifestyle support.
